Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(1-carbamoyl-2-phenyl-ethyl) butyramide
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Topical, Cutaneous
01
Overview
N-(1-carbamoyl-2-phenyl-ethyl) butyramide, also known as FBA or Phenylalanine Butyramide (PBA), is a butyrate releaser and derivative of butyric acid and the amino acid phenylalanine. It is a solid, odorless, and tasteless compound that is stable at gastric pH and designed to release butyrate constantly throughout the gastrointestinal tract. Butyrate, a short-chain fatty acid, is a major gut microbiota metabolite known for its pivotal role in maintaining gut and skin health. FBA/PBA acts as a histone deacetylase inhibitor and modulates innate immunity biomarkers. It has demonstrated beneficial effects in improving gut barrier function, exerting anti-inflammatory and antioxidant effects, enhancing keratinocyte function, promoting wound healing, and inhibiting tyrosinase. It is being investigated for applications in conditions such as atopic dermatitis, photo-damage, and as a protective agent against SARS-CoV-2 infection.
- Other names
- ButyramidePhenylalanine Butyramide
02
Targets
HDAC9ACE2 (Angiotensin-converting enzyme 2)CAMP (Cathelicidin antimicrobial peptide)COL1 (Collagen type I)ELN (Elastin)HDAC (HDAC family)DEFB4A (Human β-defensin-2)IL15 (Interleukin 15)CCL2 (C-C motif chemokine 2)NF-κBNRP1 (Neuropilin-1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)OCLN (Occludin)TMPRSS2 (Transmembrane protease serine 2)TNFA (Tumor necrosis factor alpha (soluble))TYR (Tyrosinase)
Beyond the preview
Go deeper on N-(1-carbamoyl-2-phenyl-ethyl) butyramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-(1-carbamoyl-2-phenyl-ethyl) butyramide.